FSD Pharma Inc. Has Received a No Objection Letter from Health …
Feb 10, 2023 · The Letter of No Objection covers the company’s proposed Phase 1 clinical trial of LUCID-21-302 or Lucid-MS, a novel drug candidate for the treatment of Multiple Sclerosis and …
FSD PHARMA ANNOUNCES US$20M AT-THE-MARKET OFFERING
FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound …
• FSD-201 is a proprietary formulation of ultra-micronized palmitoylethanolamide (PEA) • FSD Pharma’s successfully completed Phase 1 clinical trial showed FSD-201 to be safe and well …
fsd-pharma
FSD Pharma 'excited' to acquire pharma group Lucid Psycheceuticals to complement existing efforts August 26, 2021 FSD Pharma signs definitive agreement to acquire 100% of Lucid …
FSD PHARMA BEGINS CONSTRUCTION OF HERITAGE MUSEUM …
Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour's drive from Toronto, FV Pharma management's mission is to transform the facility into the largest …
FSD Pharma Inc. in INK Research
Feb 3, 2023 · FSD Pharma is bringing innovative neuro disorders therapies to millions of patients in need.
Jul 13, 2020 · FSD Pharma Announces US$20M At-The-Market Offering TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the …
Nov 6, 2018 · Dr. Raza Bokhari, CEO of FSD Pharma stated, “This positive ISA report for CBD combination therapy is welcome news for FSD Pharma. We expect SciCann’s Steady …
DR. RAZA BOKHARI, FSD PHARMA EXECUTIVE CO-CHAIRMAN …
Jun 4, 2019 · FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid …
Nov 26, 2018 · TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of Rupert …